BioSpace News Archive

Peptilogics, a clinical-stage biotechnology company, today announced new top-line interim data for PLG0206 in periprosthetic joint infection (PJI) patients from their ongoing Phase 1b trial.

Maravai LifeSciences, Inc. announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.

BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for HER2-positive breast cancer patients.

InsightRX today announced results of a data analysis by Mount Nittany Medical Center showing how deploying InsightRX’s Bayesian software integrated with PINC AI™ Clinical Surveillance powered by TheraDoc® for monitoring vancomycin dosing helped increase efficiency and optimized pharmacist workflow compared to industry benchmarks.

Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for indication expansion of the Quanta™ Dialysis System, a compact and easy-to-use hemodialysis device.

Burst Diagnostics, a pioneering force in rapid, point-of-care diagnostic solutions, proudly announces the appointments of Drs. Larry Jia and Mary Gunn to its Board of Directors.

Avanzanite Bioscience B.V., a specialty commercial-stage pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, announced the appointment of Marc-Andre Goldschmidt as Country Manager of Germany.

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, announced the appointment of Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development.

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ (“CELZ-201-DDT”).

AMO Pharma Limited (“AMO Pharma”) today announced initial preclinical data from a study of the use of the company’s investigational therapy AMO-02 in the treatment of Duchenne muscular dystrophy (DMD).